Slide 6 of 76
Notes:
Foisy MM, Gough K, Quan C, Harris K, Ibanez D, Phillips A.
Hospitalization due to adverse drug reactions and drug interactions before and after highly active antiretroviral therapy. Can J Inf Dis 2000;11(4):193-201.
Two large retrospective chart reviews of inpatients receiving a protease inhibitor showed that approximately 50% were receiving at least 1 other drug that could potentially result in a drug interaction.[2,3] These data highlight the importance of prospective monitoring for drug interactions in patients receiving protease inhibitors. The rate was increased in patients with more advanced disease (lower CD4+ cell counts)[2] and approximately half of the drug interactions were deemed to be potentially serious or life-threatening.[3]
van Cleef GF, Fisher EJ, Polk RE. Drug interaction potential with inhibitors of HIV protease. Pharmacotherapy 1997; 17: 774-8 Preston SL, Postelnick M, Purdy BD, et al. Drug interactions in HIV-positive patients initiated on protease inhibitor therapy. AIDS 1998; 12: 228-30
